Navigation Links
Favrille Announces Results From Study Showing Enhanced Activity,From Insect Cell-Derived Immunotherapy for Lymphoma

Data Reported at American Association for Cancer Research Annual Meeting

SAN DIEGO, April 18, 2007 /PRNewswire-FirstCall/ -- Favrille, Inc. , a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, announced results from a new study showing enhanced activity from insect-cell derived idiotype (Id) proteins, a key component in the Company's Id/KLH immunotherapy product candidate FavId(R) for B-cell non-Hodgkin's lymphoma (NHL), compared to Id proteins produced using mammalian cells. The data were reported today at the American Association for Cancer Research (AACR) Annual Meeting in Los Angeles.

"Our data show that production of recombinant Id proteins via an insect cell system results in a structurally different antigen with improved immunogenicity compared to mammalian cell-derived Id proteins," said co-author John Timmerman, M.D., and Assistant Professor of Medicine, Division of Hematology and Oncology at the University of California, Los Angeles, where much of the study was performed. "This in turn may lead to improved activity of the final Id-KLH immunotherapy for lymphoma."

A copy of the poster presented by Dr. Timmerman, entitled "Enhanced Immunostimulation by a Therapeutic Lymphoma Idiotype Vaccine Produced in Insect Cells Involves Mannose Receptor Targeting to Antigen Presenting Cells," is now available on the Investor Relations section of Favrille's web site at www.favrille.com.

"This study demonstrates that Id protein produced by insect cell lines possesses an enhanced ability to interact with dendritic cells compared to the same protein produced in mammalian cells, which in turn stimulates an enhanced immune response," said Daniel Gold, Ph.D., Favrille's Chief Scientific Officer. "These data help support our belief that the use of insect cells provides not only the most eff
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkins Lymphoma in Europe
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:6/19/2013)... , June 19, 2013   Voices Against ... finding a cure for brain cancer, today announced that ... grant to support the clinical investigation of Toca 511 ... high grade glioma brain cancer (Grade 3 or Grade ... novel treatments for advanced cancer, with an initial focus ...
(Date:6/19/2013)... BETHESDA, Md. , June 19, 2013 /PRNewswire/ -- ... "Company"), an American healthcare company providing services in ... of United Family Healthcare, a network of private ... official opening of its Beijing United Family Rehabilitation ... development projects of the United Family Healthcare ("UFH") ...
(Date:6/19/2013)... -- BD Biosciences, a segment of BD (Becton, Dickinson and ... technology company, today announced the launch of the BD ... of high-performance research flow cytometers. The BD ... most compact footprint in its class at just 30" x ... (76.2 cm). Recognizing that space is a valuable commodity in ...
Breaking Medicine Technology:Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 2Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 3Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 4Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 5New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2
... DENVER, Nov. 12 Corgenix Medical Corporation (OTC Bulletin Board: ... today reported sales of $2,044,967 for the first fiscal quarter ... ended September 30, 2008, an increase of 2.2%. , The ... compared with an operating loss of $94,133 for the first ...
... WASHINGTON, Nov. 12 Women,s Health Weekly recently ... are working on nearly 1,000 life-changing medicines for diseases affecting ... the Pharmaceutical Research and Manufacturers of America ... Food and Drug Administration or are in human clinical trials. ...
Cached Medicine Technology:Corgenix Reports Financial Results for First Quarter of Fiscal 2010 2Corgenix Reports Financial Results for First Quarter of Fiscal 2010 3Record Number of New Medicines in Development for Women 2
(Date:6/19/2013)... study led by researchers at The University of Texas ... to show remarkable promise for the treatment of relapsed ... recent interim findings of the 18-center Phase 2 study ... of Medicine . Previous interim findings were presented in ... Annual Meeting and Exposition. , Unprecedented results, ...
(Date:6/19/2013)... In a study published in the June 19 online ... team led by researchers from the University of California, ... cellular events that take place when cardiac regeneration occurs ... provide evidence that various cell lines in the heart ... cell types, than previously thought. , More importantly, the ...
(Date:6/19/2013)... A new understanding of the genetic process that ... of potentially dangerous lesions for some women, and also ... therapies in certain cases suggesting they could actually ... The analysis provides a clearer picture of the chromosomal ... papillomavirus sometimes leads to chronic infection and, in less ...
(Date:6/19/2013)... Iowa study reveals significant disparities between minority and ... abuse treatment programs. Moreover, these disparities vary widely ... suggest that for most states there,s something amiss," ... and biostatistics. "There are strong racial and ethnic ... substance abuse treatment programs successfully, and those disparities ...
(Date:6/19/2013)... 19, 2013) In early April, senior leaders from ... Hartford, Connecticut, to discuss one question: how can first ... , The preliminary results of this discussion are ... Events: The Hartford Consensus ," a concept paper published ... Journal of Trauma and Acute Care Surgery , ...
Breaking Medicine News(10 mins):Health News:Ibrutinib continues strong showing against mantle cell lymphoma 2Health News:Fate of the heart: Researchers track cellular events leading to cardiac regeneration 2Health News:Genetics of cervical cancer raise concern about antiviral therapy in some cases 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3Health News:Hartford consensus aims to improve survival after mass shootings 2
... , His Longevity with the Deadly Disease Inspires ... Sept. 4 When Jerry Lewis takes the stage again on Labor Day ... the same lung disease as he will be watching - and not just ... from the funny man who suffers from a not-so-funny and little known fatal ...
... following is the Labor Day message of Stuart Appelbaum. Appelbaum is president of ... www.rwdsu.org , , NEW YORK, Sept. 4 ... the worst of times and the best of times. , , ... and incompetence our country is now in the midst of its greatest economic ...
... SHENZHEN, China, Sept. 4 /PRNewswire-FirstCall/ - Hard to ... its China based subsidiary Mellow Hope, has just ... Hydrolysate for Injection (Brand name: NUTRIPROTEIN) in India. ... for the brain. It helps CNS in multiple ...
... social exclusion, have health problems, study suggests, , FRIDAY, ... considered a depressant, teetotalers as well as heavy drinkers ... than moderate tipplers, a new study has found. , ... don,t drink report having fewer friends than drinkers do, ...
... ... Chain Drug Stores (NACDS) President and Chief Executive Officer Steven C. Anderson, IOM, CAE ... First Circuit ruling on September 3, 2009, upholding the reduction of average wholesale prices ... Alexandria, ...
... SHENYANG, China, Sept. 4 /PRNewswire-Asia/ -- ... wholly-owned subsidiary of China,s,leading IT solutions & services ... its development strategy and new products,officially launching three ... 16 multi-slice CT scanner, Sparkler 1.5T superconductive MRI, ...
Cached Medicine News:Health News:The Show Goes on for Pulmonary Fibrosis Patient Jerry Lewis 2Health News:The Show Goes on for Pulmonary Fibrosis Patient Jerry Lewis 3Health News:Stand Up for Health Care! A Labor Day Message From RWDSU President Stuart Appelbaum 2Health News:Stand Up for Health Care! A Labor Day Message From RWDSU President Stuart Appelbaum 3Health News:Hard To Treat Diseases (HTDS) Completes Injection Clinical Trial 2Health News:Hard To Treat Diseases (HTDS) Completes Injection Clinical Trial 3Health News:Non-Drinkers More Likely to Be Anxious, Depressed 2Health News:NACDS: Court Ruling on AWPs Shifts "Urgency for Action" to States 2Health News:Neusoft Announces New Releases of Flagship Medical Products 2
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
... Finnpipette Focus from Thermo Labsystems ... ergonomics with uncompromising performance. ... offers a custom fit for ... shorter tip cones allow easier ...
... A fixed pipette is ... a single volume. Fixed volume ... and advantages as other Finnpipette ... design, Super blow-out (1-40ul), Soft-touch ...
... the borders of stereomicroscopy with increase ... high-contrast images and significantly more image ... resolution and contrast. The innovative operating ... all essential functions of a stereomicroscope ...
Medicine Products: